Sanitization Method for Affinity Chromatography Matrices
The invention discloses a method for cleaning or sanitization of an affinity chromatography matrix, comprising the steps of: a) providing an affinity chromatography matrix having oxidation-tolerant proteinaceous ligands coupled to a support, b) contacting the matrix with a sanitization solution comprising at least one oxidant defined by formula I, R—O—O—H (I) wherein R is hydrogen or an acyl group R′—C(O)—, with R′ being a hydrogen or a methyl, ethyl or propyl group.
1 . A method for cleaning or sanitization of an affinity chromatography matrix, comprising the steps of:
a) providing an affinity chromatography matrix having oxidation-tolerant proteinaceous ligands coupled to a support, and
b) contacting said matrix with a sanitization solution comprising at least one oxidant defined by formula I,
R—O—O—H (I)
wherein R is hydrogen or an acyl group R′—C(O)—, with R′ being a hydrogen or a methyl, ethyl or propyl group.
2 . The method of claim 1 , wherein said proteinaceous ligands comprise or consist essentially of one or more immunoglobulin-binding domains derived from a bacterial protein.
3 . The method of claim 1 , wherein the concentration of said oxidant in said sanitization solution is 0.01-1 mol/l.
4 . The method of claim 1 , wherein the pH of said sanitization solution is 2-12, such as 2-4 or 2-3.
5 . The method of claim 1 , wherein said oxidant is selected from the group consisting of hydrogen peroxide, performic acid and peracetic acid.
6 . The method of claim 1 , wherein said sanitization solution comprises a mixture of at least two oxidants defined by formula I, such as a mixture of hydrogen peroxide with performic or peracetic acid.
7 . The method of claim 1 , wherein the total concentration of oxidants defined by formula I is 0.01-1 mol/l.
8 . The method of claim 1 , wherein in step b) the matrix is incubated with said sanitization solution for 1 min-24 h, such as 5 min-24 h or 15 min-3 h.
9 . The method of claim 1 , wherein said matrix retains at least 80%, such as at least 90%, of its binding capacity for a target protein, such as an immunoglobulin, after step b).
10 . The method of claim 2 , wherein said bacterial protein is selected from the group consisting of Staphylococcus Protein A, Peptostreptococcus Protein L and Streptococcus Protein G, such as from the group consisting of Streptococcus Protein A and Peptostreptococcus Protein L.
11 . The method of claim 2 , wherein said ligands comprise or consist essentially of homo- or heteromultimers of immunoglobulin-binding domains derived from a bacterial protein
12 . The method of claim 2 , wherein said immunoglobulin-binding domains have at least 80%, such as at least 90 or 95%, homology with Domain E, D, A, B or C of Staphylococcus Protein A, with Protein Z or with Domain 1, 2, 3, 4 or 5 of Peptostreptococcus Protein L.
13 . The method of claim 2 , wherein said immunoglobulin-binding domains are defined by, or have at least 80%, such as at least 90 or 95% sequence homology with, an amino acid sequence selected from the group consisting of SEQ ID NO: 1-11.
14 . The method of claim 2 , wherein said immunoglobulin-binding domains are defined by, or have at least 90%, such as at least 95 or 98% sequence homology with, an amino acid sequence selected from the group consisting of SEQ ID NO: 12-16.
15 . The method of claim 1 , wherein said ligands comprise Staphylococcus Protein A or an alkali-stabilized immunoglobulin-binding variant of Staphylococcus Protein A.
16 . The method of claim 1 , wherein said ligands comprise Peptostreptococcus Protein L or an alkali-stabilized immunoglobulin-binding variant of Peptostreptococcus Protein L.
17 . The method of claim 1 , wherein said affinity chromatography matrix is selected from the group consisting of Capto™ L, MabSelect™, MabSelect Xtra, ProSep™-A, ProSep Ultra Plus, AbSolute™, CaptivA™ PriMab™ and Protein A Diamond or from the group consisting of MabSelect SuRe, MabSelect SuRe LX, Eshmuno™ A, Toyopearl™ AF-rProtein A, Amsphere™ Protein A and KanCapA™.
18 . The method of claim 1 , wherein said support comprises porous particles or a porous membrane.
19 . The method of claim 1 , wherein said support is selected from the group consisting of silica, glass and hydroxyfunctional polymers.
20 . The method of claim 1 , wherein said support is a crosslinked polysaccharide.
21 . The method of claim 1 , wherein said support is crosslinked agarose, such as rigid crosslinked agarose.
22 . The method of claim 2 , comprising, before step b), a step a′) of contacting said matrix with a solution comprising an immunoglobulin to adsorb said immunoglobulin and subsequently contacting said matrix with an elution solution to desorb said immunoglobulin.
23 . The method of claim 22 , wherein step a′) is repeated at least 10 times, such as at least 25 times before step b).
24 . The method of claim 1 , wherein in step b) the content of viable bacteria, vegetative bacteria and/or spores is reduced by at least 3 log 10 , such as at least 5 log 10 or at least 6 log 10 .
25 . The method of claim 2 , wherein the IgG-binding capacity of said matrix after step b) is at least 95%, such as at least 97%, of the IgG-binding capacity of said matrix before step b).
26 . The method of claim 1 , wherein said matrix is packed in a chromatography column.
27 . The method of claim 26 , wherein said chromatography is a single use column or a column manufactured from thermoplastic and elastomeric components.
28 . A method of using a solution comprising an oxidant defined by formula I,
R—O—O—H (I)
wherein R is hydrogen or an acyl group R′—C(O)—, with R′ being a hydrogen or a methyl, ethyl or propyl group, the method comprising sanitizing with the solution an affinity chromatography matrix having proteinaceous ligands coupled to a support, wherein said proteinaceous ligands comprise or consist essentially of one or more immunoglobulin-binding domains derived from a bacterial protein.
29 . The method of claim 28 , wherein said proteinaceous ligands comprise or consist essentially of one or more immunoglobulin-binding domains derived from a bacterial protein.
30 . The method of claim 28 , wherein said sanitization provides at least 5 or 6 log reduction of the viable bacterial spore concentration.
31 . The method of claim 30 , wherein the reduction of the viable bacterial spore concentration is assessed with Bacillus subtilis spores.
32 . A method for sanitization of a chromatography matrix, comprising the steps of:
a) providing a chromatography matrix having oxidation-tolerant ligands coupled to a rigid crosslinked agarose support,
b) contacting said matrix with a sanitization solution comprising an oxidant defined by formula I,
R—O—O—H (I)
wherein R is hydrogen or an acyl group R′—C(O)—, with R′ being a hydrogen or a methyl, ethyl or propyl group.
33 . The method of claim 32 , wherein the concentration of said oxidant in said sanitization solution is 0.01-1 mol/l.
34 . The method of claim 32 , wherein the pH of said sanitization solution is 2-12, such as 2-4, or 2-3.
35 . The method of claim 32 , wherein in step b) the matrix is incubated with said sanitization solution for 1 min-24 h, such as 5 min-24 h or 15 min-3 h.